Yellowstone Biosciences launches with £16.5 million to pioneer soluble bispecific TCR-based therapies for cancer

Contributed by: Business Wire

Logo

Tags

Research

Medical Devices

Biotechnology

Other Health

Health

Pharmaceutical

Other Science

Science

Oncology

Yellowstone Biosciences

More Like This

Yellowstone Biosciences Appoints James (“Jim”) MacDonald as Chief Executive Officer

PR Newswire associated0

Gyala Therapeutics unveils first-in-class CAR-T therapy targeting CD84 showing strong preclinical efficacy in hard-to-treat leukemias

Brenus Pharma Publishes Promising Proof of Concept Results of their Therapeutic Platform in the Scientific Frontiers in Oncology Journal. (1)

PR Newswire associated0

Gyala Therapeutics initiates Phase I/IIa clinical trial of a CAR-T cell therapy in acute leukemias with limited treatment options

Conformation-X Therapeutics Bolts out of Stealth, Securing Over $13.5M in Funding to Propel Its Innovative Immune-Oncology Pipeline

GlobeNewswire associated0

4BIO Capital Portfolio Company Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy

Biocytogen Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma

PR Newswire associated0

Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual Congress